VectorY Therapeutics at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
VectorY Therapeutics brings 5 presentations to ESGCT 2026 in Hamburg. Its work centres on AAV-delivered antibody therapies for motor neuron disease and Huntington's disease, including dose thresholds set from single-cell measurements in ALS neurons. A second strand covers insect cell manufacturing and the analytical work behind larger-scale production.
| Organization | ESGCT 2026 Attendance |
|---|---|
VectorY Therapeutics Amsterdam, Netherlands | |
Develops AAV-delivered vectorized antibody therapies for neurodegenerative diseases such as ALS and Huntington's disease. | Poster Wed Oct 28 1:30pm–3:30pm A scalable and quality driven insect cell–baculovirus manufacturing platform enables 1000L production of VTx-002, an AAV based vectorized antibody for ALS Poster Wed Oct 28 1:30pm–3:30pm From Single-Cell Analysis to Clinical Dose: Setting the Therapeutic Threshold for VTx-002 in ALS Motor Neurons Poster Wed Oct 28 1:30pm–3:30pm Leveraging Analytical Characterization to Drive Scalable GMP Manufacturing and Regulatory Advancement of VTx-002, an AAV-based vectorized antibody for ALS Poster Wed Oct 28 1:30pm–3:30pm No DRG toxicity in AAV5-vectorized antibody therapy after intracisternal magna administration in nonhuman primates Poster Wed Oct 28 1:30pm–3:30pm Validation of HTT CAG50 iPSC‑Derived Neurons to Support Drug Discovery in Huntington’s Disease Rare and inherited disease |
Instantly find 20 buyers from VectorY Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction